The Relative Strength (RS) Rating for Vericel (VCEL) stock entered a higher percentile Monday, as it got a lift from 69 to 79.
↑ XIBD's proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matched up against all other stocks.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Vericel stock can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Vericel stock broke out on Nov. 7 and has moved more than 5% past a 50.00 entry in a first-stage double bottom, meaning it's extended and now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The biotech company reported 0% EPS growth in its most recent report, while sales growth came in at 27%.
Vericel stock earns the No. 45 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。